The use of a STING agonist can enhance the activation, cytotoxicity and anti-tumor effects of natural killer (NK) cells independently of CD8+ T cells, thus improving the clearance of tumors resistant to CD8+ T cells [109]. The gene discussed is STING1; the disease is neoplasm.